NDA 019845 · Novartis
Betoptic S
Betaxolol Hydrochloride · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Dec 29, 1989
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 1 recruiting
FAERS reports
521
400 serious, 44 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 22, 2025.
BETOPTIC S ® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. BETOPTIC S is a beta-adrenergic receptor inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension. ( 1 )
Mechanism: Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor inhibitor, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic receptor inhibitors reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function. When instilled in the eye, BETOPTIC S has the action of reducing elevated...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 8, 2007 Supplement 20 · Efficacy · priority review Pediatric Written RequestPediatric Medical ReviewPediatric Medical Review
- Dec 29, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
- BETOPTIC S · BETAXOLOL HYDROCHLORIDE EQ 0.25% BASE · SUSPENSION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Betaxolol" as an intervention, any sponsor and status, largest first.
- Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT02617459 · 366 participants · Start Jan 4, 2019 · Primary completion Jul 1, 2021
Drug: Levobetaxolol eye drops; Betaxolol eye drops · For: Primary Open-angle Glaucoma; Ocular Hypertension
Sites: Guangzhou, China
- Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00061542 · 105 participants · Start Jan 2003 · Primary completion Nov 2006
Drug: BETOPTIC S (betaxolol HCl); Timolol Gel-forming Solution (TGFS) · For: Glaucoma; Ocular Hypertension
Sites: Fort Worth, Texas
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated HypertensionCompleted
Medical University of South CarolinaAcademic, hospital or other
NCT00684489 · 52 participants · Start Sep 2003 · Primary completion Mar 2005
Drug: clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med. · For: Hypertension
Smith-Kettlewell Eye Research InstituteAcademic, hospital or other
NCT01660620 · 23 participants · Start Apr 2011 · Primary completion Nov 2011
Drug: Betaxolol; topical betaxolol · For: Development of Side Effects From Betaxolol
- A Preliminary Study for INFORMEDRecruiting
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT05585125 · 18 participants (planned) · Start Feb 7, 2024 · Primary completion Feb 2027
Drug: Beta blocker; Beta blocker · For: Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction and 2 more
Sites: New York, New York
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT05019027 · 14 participants · Start Jan 31, 2024 · Primary completion Jun 4, 2026
Drug: Beta blocker · For: Cardiac Amyloidosis; Heart Diseases; TTR Cardiac Amyloidosis
Sites: New York, New York
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT04757584 · 9 participants · Start Apr 1, 2021 · Primary completion Apr 28, 2023
Drug: Beta blockers · For: Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction and 2 more
Sites: New York, New York
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT04767061 · 9 participants · Start Apr 1, 2021 · Primary completion Apr 28, 2022
Drug: Beta blockers · For: Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction and 2 more
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall67
- dyspnoea61
- drug ineffective50
- pain39
- dizziness38
- asthma35
- eye irritation35
- fatigue34
- nausea33
- haemorrhage32
- headache31
- hypersensitivity31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 11 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 8 |
| 2009 | 11 |
| 2010 | 11 |
| 2011 | 13 |
| 2012 | 13 |
| 2013 | 10 |
| 2014 | 9 |
| 2015 | 14 |
| 2016 | 19 |
| 2017 | 37 |
| 2018 | 48 |
| 2019 | 64 |
| 2020 | 31 |
| 2021 | 24 |
| 2022 | 43 |
| 2023 | 31 |
| 2024 | 55 |
| 2025 | 26 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Betoptic S (Betaxolol HCl)
2024 spending
$3.7M
Beneficiaries
1,971
7,033 claims
Per beneficiary
$1,875
$35.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,215,153 |
| 2021 | $5,501,373 |
| 2022 | $4,820,042 |
| 2023 | $4,403,689 |
| 2024 | $3,695,025 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
Heijl A, Leske MC, Bengtsson B, et al. · Arch Ophthalmol 2002 · Clinical Trial, Randomized Controlled Trial
- Early Manifest Glaucoma Trial: design and baseline data.
Leske MC, Heijl A, Hyman L, et al. · Ophthalmology 1999 · Clinical Trial, Multicenter Study
- Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.
Wong GW, Boyda HN, Wright JM · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Betaxolol and timolol. A comparison of efficacy and side effects.
Berry DP, Van Buskirk EM, Shields MB · Arch Ophthalmol 1984 · Clinical Trial, Comparative Study
- Longterm visual field follow-up of glaucoma patients treated with beta-blockers.
Kaiser HJ, Flammer J, Stümpfig D, et al. · Surv Ophthalmol 1994 · Clinical Trial, Comparative Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.